News & Events about Regeneron Pharmaceuticals Inc.
Business Wire
5 months ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (Regeneron or the Company) (NASDAQ: REGN) for violations of the securities laws. The investigation focuses on whether the Company...
Stock Options Channel
7 months ago
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Wynn Resorts Ltd (WYNN), where a total of 13,548 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 64.6% of WYNN's average daily ...
Ticker Report
7 months ago
Cyndeo Wealth Partners LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN Get Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 753 shares of the ...
Globe Newswire
8 months ago
Dupixent demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placeboFirst and only ...
Globe Newswire
8 months ago
First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo First and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to placebo (77 mL in FEV1) First and only ...